Abstract
G protein coupled receptors (GPCRs) are extremely important drug targets and the β-arrestin intracellular scaffolding and adaptor proteins regulate major aspects of their pharmacology. β-arrestin binding to activated, GPCR kinase (GRK)-phosphorylated receptors has the capacity to terminate G protein coupling, internalize the receptors into clathrincoated vesicles and establish a secondary signaling complex independent of G protein signaling. These events appear to be differentially regulated by GRK phosphorylation, ubiquitination and potentially β-arrestin oligomerization, which are likely to be highly receptor and cell-type dependent. The role of β-arrestins in switching from G-protein dependent to independent signaling places them in a pivotal position to dictate the downstream effects of ligand binding. Consequently, we must appreciate the functioning of these molecules as we strive to discover and optimize new GPCR drug therapies for endocrine, metabolic and immune disorders.
Keywords: G protein coupled receptor, GPCR, β-arrestin, endocytosis, internalisation
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: G Protein Coupled Receptors as Drug Targets: The Role of β-Arrestins
Volume: 8 Issue: 1
Author(s): Jasmin R. Dromey and Kevin D.G. Pfleger
Affiliation:
Keywords: G protein coupled receptor, GPCR, β-arrestin, endocytosis, internalisation
Abstract: G protein coupled receptors (GPCRs) are extremely important drug targets and the β-arrestin intracellular scaffolding and adaptor proteins regulate major aspects of their pharmacology. β-arrestin binding to activated, GPCR kinase (GRK)-phosphorylated receptors has the capacity to terminate G protein coupling, internalize the receptors into clathrincoated vesicles and establish a secondary signaling complex independent of G protein signaling. These events appear to be differentially regulated by GRK phosphorylation, ubiquitination and potentially β-arrestin oligomerization, which are likely to be highly receptor and cell-type dependent. The role of β-arrestins in switching from G-protein dependent to independent signaling places them in a pivotal position to dictate the downstream effects of ligand binding. Consequently, we must appreciate the functioning of these molecules as we strive to discover and optimize new GPCR drug therapies for endocrine, metabolic and immune disorders.
Export Options
About this article
Cite this article as:
Dromey R. Jasmin and Pfleger D.G. Kevin, G Protein Coupled Receptors as Drug Targets: The Role of β-Arrestins, Endocrine, Metabolic & Immune Disorders - Drug Targets 2008; 8 (1) . https://dx.doi.org/10.2174/187153008783928352
DOI https://dx.doi.org/10.2174/187153008783928352 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Roles of Mesenchymal Stem Cells in Tissue Repair and Disease Modification
Current Stem Cell Research & Therapy Mesenchymal Stem Cells: New Approaches for the Treatment of Neurological Diseases
Current Stem Cell Research & Therapy Glutaminase Isoenzymes as Key Regulators in Metabolic and Oxidative Stress Against Cancer
Current Molecular Medicine Aldose Reductase in Diabetic Microvascular Complications
Current Drug Targets Vascular and Cardiac Oxidative Stress and Inflammation as Targets for Cardioprotection
Current Pharmaceutical Design Targeting mTOR Signaling in Type 2 Diabetes Mellitus and Diabetes Complications
Current Drug Targets PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design Identification and Treatment of Patients with Early COPD
Current Respiratory Medicine Reviews Acute Cardioembolic Cerebral Infarction: Answers to Clinical Questions
Current Cardiology Reviews Cell Responses to Oxidative Stressors
Current Pharmaceutical Design Chemokine-Chemokine Receptor Network in Immune Cell Trafficking
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Promotion of Insulin-Like Growth Factor-I Production by Sensory Neuron Stimulation; Molecular Mechanism(s) and Therapeutic Implications
Current Medicinal Chemistry Molecular Biological Roles of Ursolic Acid in the Treatment of Human Diseases
Current Bioactive Compounds ATP Citrate Lyase Inhibitors as Novel Cancer Therapeutic Agents
Recent Patents on Anti-Cancer Drug Discovery Inflammation and Chronic Oxidative Stress in Radiation-Induced Late Normal Tissue Injury: Therapeutic Implications
Current Medicinal Chemistry Therapeutic Management of COVID-19 Patients: Clinical Manifestation and Limitations
Current Pharmaceutical Design Endotoxin, TLR4 Signaling and Vascular Inflammation: Potential Therapeutic Targets in Cardiovascular Disease
Current Pharmaceutical Design Cardiosphere-derived Progenitor Cells for Myocardial Repair Following Myocardial Infarction
Current Pharmaceutical Design Calcium Channel Mutations in Cardiac Arrhythmia Syndromes
Current Molecular Pharmacology The Applications of Targeting Anti-Cancer Agents in Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry